Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41569-020-00445-9 http://scihub22266oqcxt.onion/10.1038/s41569-020-00445-9 33037325!7545156!33037325     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33037325&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Nat+Rev+Cardiol 2021 ; 18 (2): 75-91 Nephropedia Template TP {{tp|p=33037325|t=2021. Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management |pdf=|usr=}}{{33037325}} gab.com Text Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management JO: Nat Rev Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33037325 #FOAvip Ambulatory monitoring is increasingly important for cardiovascular care but is often limited by the unpredictability of cardiovascular events, the intermittent nature of ambulatory monitors and the variable clinical significance of recorded data in patients. Technological advances in computing have led to the introduction of novel physiological biosignals that can increase the frequency at which abnormalities in cardiovascular parameters can be detected, making expert-level, automated diagnosis a reality. However, use of these biosignals for diagnosis also raises numerous concerns related to accuracy and actionability within clinical guidelines, in addition to medico-legal and ethical issues. Analytical methods such as machine learning can potentially increase the accuracy and improve the actionability of device-based diagnoses. Coupled with interoperability of data to widen access to all stakeholders, seamless connectivity (an internet of things) and maintenance of anonymity, this approach could ultimately facilitate near-real-time diagnosis and therapy. These tools are increasingly recognized by regulatory agencies and professional medical societies, but several technical and ethical issues remain. In this Review, we describe the current state of cardiovascular monitoring along the continuum from biosignal acquisition to the identification of novel biosensors and the development of analytical techniques and ultimately to regulatory and ethical issues. Furthermore, we outline new paradigms for cardiovascular monitoring. Twit Text FOAVip Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management ????Nat Rev Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33037325 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33037325 #FOAvip English Wikipedia <ref>{{Cite pmid|33037325}}</ref> Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management #MMPMID33037325 Krittanawong C; Rogers AJ; Johnson KW; Wang Z; Turakhia MP; Halperin JL; Narayan SM Nat Rev Cardiol 2021[Feb]; 18 (2): 75-91 PMID33037325show ga Ambulatory monitoring is increasingly important for cardiovascular care but is often limited by the unpredictability of cardiovascular events, the intermittent nature of ambulatory monitors and the variable clinical significance of recorded data in patients. Technological advances in computing have led to the introduction of novel physiological biosignals that can increase the frequency at which abnormalities in cardiovascular parameters can be detected, making expert-level, automated diagnosis a reality. However, use of these biosignals for diagnosis also raises numerous concerns related to accuracy and actionability within clinical guidelines, in addition to medico-legal and ethical issues. Analytical methods such as machine learning can potentially increase the accuracy and improve the actionability of device-based diagnoses. Coupled with interoperability of data to widen access to all stakeholders, seamless connectivity (an internet of things) and maintenance of anonymity, this approach could ultimately facilitate near-real-time diagnosis and therapy. These tools are increasingly recognized by regulatory agencies and professional medical societies, but several technical and ethical issues remain. In this Review, we describe the current state of cardiovascular monitoring along the continuum from biosignal acquisition to the identification of novel biosensors and the development of analytical techniques and ultimately to regulatory and ethical issues. Furthermore, we outline new paradigms for cardiovascular monitoring. |*Cardiovascular Diseases/diagnosis/therapy[MESH] |*Machine Learning[MESH] |*Monitoring, Ambulatory/instrumentation[MESH] |Humans[MESH]Integration of novel monitoring devices with machine learning technolo(epmc).pdf DeepDyve Pubget Overpricing